Observes safety of OBIZUR in adults with a rare bleeding disorder
Watches how OBIZUR works in adults with acquired hemophilia A.
Plain-language title generated from the registry record
Registry title: A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea
Key facts
- Where
- Seoul and Ulsan, South KoreaSee the 4 sites
Where in South Korea
- Ewha Womans University Medical CenterSeoul, South KoreaTaking people
- Kyung Hee University Hospital at GangdongSeoul, South KoreaTaking people
- The Catholic University of Korea, Seoul ST. Mary's HospitalSeoul, South KoreaTaking people
- Ulsan University HospitalUlsan, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Takeda
- Trial code
- NCT06550882
- Record updated
- 9 November 2026
- Original description
Acquired hemophilia A (AHA) is a rare bleeding condition which prevents blood clotting. Acquired means that people are not born with this condition or have a family history of blood clotting conditions. People living with AHA can have sudden and severe bleeding. They also have longer bleeding compared to people without AHA.Read full original descriptionShow less
Post-Marketing Surveillance (Use-result Surveillance) of OBIZUR Injection [Susoctocog Alpha (Porcine Antihemophilic Factor VIII, Recombinant)] for the Approved Indications in South Korea
Acquired hemophilia A (AHA) is a rare bleeding condition which prevents blood clotting. Acquired means that people are not born with this condition or have a family history of blood clotting conditions. People living with AHA can have sudden and severe bleeding. They also have longer bleeding compared to people without AHA.
The main aim of the study is to learn how safe OBIZUR is in adults with AHA.
Other aims are to see how effective OBIZUR is to control bleeding and how treatment is used in a routine clinical practice setting.
The treatment of the participants will be determined by the treating physicians.
During the study, data already existing in the participants' medical record and new data will be collected.
Inclusion: Participants with AHA; Participants who are determined to have the clinical need to receive Obizur treatment; Participants aged 18 years or older at time of initiation of Obizur treatment; Participants agreed to participate in the study and voluntarily signed the informed consent.
Exclusion: Participants with Congenital Hemophilia A with Inhibitors (CHAWI); Participants who has participated in another clinical study involving a medicinal product or device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving a medicinal product or device during the course of the study; Participants with hypersensitivity to any of the components of this drug; Participants for whom Obizur treatment is contraindicated as per product label.